COMPANY PROFILE // THE 014 REPORT
Puma Biotechnology, Inc.
PBYI (Nasdaq) · Formerly: INNOVATIVE ACQUISITIONS CORP
Assembled from 4 government sources in 2.0 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
No flag from the records checked. 24 of 26 lists and sources checked came back clear (panel below).
✓ SEC filings✓ SAM registrationpossible match✓ State registrationpossible match✗ LEI✗ IRS return✗ Website✗ Lobbying registration
No LEI, no IRS return, no website, no lobbying registration on record.
PUMA BIOTECHNOLOGY, INC. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Los Angeles, CA; listed as PBYI (Nasdaq).[source] It reported revenue of $228.4 million for the fiscal year ended 2025-12-31.[source] It has filed 52 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13G, filed 2026-11-16.[source] Its largest institutional holders on 13F filings are ACORN CAPITAL ADVISORS, LLC, BlackRock, Inc., AMERICAN CENTURY COMPANIES INC (as of 2026-06-30).[source] 24 of 26 lists and sources checked came back clear; the rest are listed with their result.[source]
- red0
- amber0
- info0
- ACORN CAPITAL ADVISORS, LLC$33.5M
- BlackRock, Inc.$30.9M
- AMERICAN CENTURY COMPANIES INC$18.8M
- RENAISSANCE TECHNOLOGIES LLC$14.9M
- VANGUARD CAPITAL MANAGEMENT LLC$14.9M
- VANGUARD PORTFOLIO MANAGEMENT LLC$14.8M
- DIMENSIONAL FUND ADVISORS LP$12.3M
- GEODE CAPITAL MANAGEMENT, LLC$10.9M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA. (Wikipedia, CC BY-SA 4.0)
Officers and directors (Forms 3, 4, 5)
- AUERBACH ALAN H · President and CEO (Director,Officer,10% owner) · latest Form 4 2026-02-20 · filing · LinkedIn search
- HUNT DOUGLAS M · See Remarks (Officer) · latest Form 4 2026-02-20 · filing · LinkedIn search
- NOUGUES MAXIMO F · Chief Financial Officer (Officer) · latest Form 4 2026-02-20 · filing · LinkedIn search
- Cesano Alessandra · Director · latest Form 4 2025-07-22 · filing · LinkedIn search
- Dorval Allison · Director · latest Form 4 2025-06-17 · filing · LinkedIn search
- MILLER MICHAEL PATRICK · Director · latest Form 4 2025-11-13 · filing · LinkedIn search
- MOYES JAY M · Director · latest Form 4 2025-06-17 · filing · LinkedIn search
- Senderowicz Adrian · Director · latest Form 4 2025-06-17 · filing · LinkedIn search
- Stuglik Brian M · Director · latest Form 4 2025-06-17 · filing · LinkedIn search
- WILSON TROY EDWARD · Director · latest Form 4 2025-06-17 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Links
- Official website (Wikidata or the SEC record)
- Wikipedia
- Wikidata
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 24 CLEAR, 2 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001401667 | source |
| UEIpossible match | JLJDGN4NRBP3 | source |
| CAGEpossible match | 7WRK3 | source |
| EIN | 77-0683487 | source |
| NY DOS ID | 4827237 | record |
| California SOS entity | 0002592358-0001-6 | record |
| California SOS entity | 1165125-10-171-1077981 | record |
| Business address (SEC) | 10880 WILSHIRE BLVD., LOS ANGELES, CA | source |
Does not exist in the records we hold: LEI, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-16 · in 116 days · Next 10-K due (period ended 2026-12-31; Accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-10 · in 171 days · Next 10-Q due (period ended 2027-03-31; Accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-07-27 · in 249 days · SAM registration expires (UEI JLJDGN4NRBP3)possible match
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Summit Therapeutics Inc. · Cesano Alessandra
- Zymeworks Inc. · Cesano Alessandra
- RIGEL PHARMACEUTICALS INC · MILLER MICHAEL PATRICK
- BioXcel Therapeutics, Inc. · MILLER MICHAEL PATRICK
- BioCardia, Inc. · MOYES JAY M
- Sintx Technologies, Inc. · MOYES JAY M
- Verastem, Inc. · Stuglik Brian M
- Kura Oncology, Inc. · WILSON TROY EDWARD
- Atrium Therapeutics, Inc. · WILSON TROY EDWARD
EVERY SOURCE · NEWEST FIRST
One timeline
- 2027-07-27 registration SAM registration expiry (UEI JLJDGN4NRBP3) · SAM.gov
- 2026-11-12 filing 144 · SEC EDGAR
- 2026-11-09 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-05 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-10-06 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-09-14 filing 144 · SEC EDGAR
- 2026-09-14 filing 144 · SEC EDGAR
- 2026-08-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-06 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-06 filing 144 · SEC EDGAR
- 2026-07-06 filing 144 · SEC EDGAR
- 2026-07-06 filing 144 · SEC EDGAR
- 2026-06-16 filing 8-K items 5.07 · SEC EDGAR
- 2026-06-12 filing 144 · SEC EDGAR
- 2026-06-12 filing 144 · SEC EDGAR
- 2026-06-12 filing 144 · SEC EDGAR
- 2026-06-12 filing 144 · SEC EDGAR
- 2026-06-12 filing 144 · SEC EDGAR
- 2026-05-07 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-07 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-28 filing DEFA14A · SEC EDGAR
- 2026-04-28 filing ARS · SEC EDGAR
- 2026-04-28 filing Proxy statement · SEC EDGAR
- 2026-04-07 filing PRE 14A · SEC EDGAR
- 2026-02-26 filing Annual report (10-K) · SEC EDGAR
- 2026-02-26 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-01-07 filing 144 · SEC EDGAR
- 2026-01-07 filing 144 · SEC EDGAR
- 2026-01-07 filing 144 · SEC EDGAR
- 2026-01-06 filing 144 · SEC EDGAR
158 earlier entries
- 2026-01-06 filing 144
- 2026-01-06 filing 144
- 2025-11-12 filing 144
- 2025-11-06 filing Quarterly report (10-Q)
- 2025-11-06 filing 8-K items 2.02,9.01
- 2025-08-07 filing Quarterly report (10-Q)
- 2025-08-07 filing 8-K items 2.02,9.01
- 2025-08-07 filing 10-Q/A
- 2025-07-18 filing 144
- 2025-07-10 insider First Form 3/4/5 on record for AUERBACH ALAN H (President and CEO)
- 2025-07-10 insider First Form 3/4/5 on record for HUNT DOUGLAS M (See Remarks)
- 2025-07-10 insider First Form 3/4/5 on record for NOUGUES MAXIMO F (Chief Financial Officer)
- 2025-07-09 filing 144
- 2025-07-09 filing 144
- 2025-07-09 filing 144
- 2025-07-08 filing 144
- 2025-07-08 filing 144
- 2025-07-08 filing 144
- 2025-06-24 filing 8-K items 5.03,9.01
- 2025-06-13 filing 144
- 2025-06-13 filing 144
- 2025-06-13 filing 144
- 2025-06-13 filing 144
- 2025-06-13 filing 8-K items 5.07
- 2025-06-13 filing 144
- 2025-06-13 filing 144
- 2025-06-13 insider First Form 3/4/5 on record for Cesano Alessandra (Director)
- 2025-06-13 insider First Form 3/4/5 on record for Dorval Allison (Director)
- 2025-06-13 insider First Form 3/4/5 on record for MILLER MICHAEL PATRICK (Director)
- 2025-06-13 insider First Form 3/4/5 on record for MOYES JAY M (Director)
- 2025-06-13 insider First Form 3/4/5 on record for Senderowicz Adrian (Director)
- 2025-06-13 insider First Form 3/4/5 on record for Stuglik Brian M (Director)
- 2025-06-13 insider First Form 3/4/5 on record for WILSON TROY EDWARD (Director)
- 2025-05-21 filing 144
- 2025-05-09 officer change 8-K items 5.02
- 2025-05-08 filing Quarterly report (10-Q)
- 2025-05-08 filing 8-K items 2.02,9.01
- 2025-04-28 filing DEFA14A
- 2025-04-28 filing ARS
- 2025-04-28 filing Proxy statement
- 2025-02-27 filing Annual report (10-K)
- 2025-02-27 filing 8-K items 2.02,9.01
- 2025-01-02 filing 144
- 2025-01-02 filing 144
- 2025-01-02 filing 144
- 2025-01-02 filing 144
- 2024-11-07 filing Quarterly report (10-Q)
- 2024-11-07 filing 8-K items 2.02,9.01
- 2024-09-16 filing 8-K items 8.01
- 2024-08-27 filing S-8
- 2024-08-15 filing 8-K items 8.01
- 2024-08-12 filing 144
- 2024-08-07 filing 8-K items 8.01
- 2024-08-01 filing Quarterly report (10-Q)
- 2024-08-01 filing 8-K items 2.02,9.01
- 2024-07-17 filing 144
- 2024-07-17 filing 144
- 2024-07-17 filing 144
- 2024-07-17 filing 144
- 2024-07-02 filing 144
- 2024-07-02 filing 144
- 2024-07-02 filing 144
- 2024-07-02 filing 144
- 2024-06-24 officer change 8-K items 5.02,5.07,9.01
- 2024-06-13 filing 144
- 2024-06-13 filing 144
- 2024-06-13 filing 144
- 2024-06-13 filing 144
- 2024-06-13 filing 144
- 2024-05-17 filing 8-K items 8.01
- 2024-05-02 filing Quarterly report (10-Q)
- 2024-05-02 filing 8-K items 2.02,9.01
- 2024-04-26 filing DEFA14A
- 2024-04-26 filing ARS
- 2024-04-26 filing Proxy statement
- 2024-03-19 filing 8-K items 8.01
- 2024-02-29 filing Annual report (10-K)
- 2024-02-29 filing 8-K items 2.02,9.01
- 2024-01-18 filing 8-K items 7.01,9.01
- 2024-01-10 filing 144/A
- 2024-01-03 filing 144
- 2024-01-03 filing 144
- 2024-01-03 filing 144
- 2024-01-03 filing 144
- 2024-01-03 filing 144
- 2023-11-07 filing 144
- 2023-11-02 filing Quarterly report (10-Q)
- 2023-11-02 filing 8-K items 2.02,9.01
- 2023-09-26 filing 8-K items 7.01
- 2023-08-18 filing 8-K items 5.03,9.01
- 2023-08-03 filing Quarterly report (10-Q)
- 2023-08-03 filing 8-K items 2.02,9.01
- 2023-07-03 filing 144
- 2023-07-03 filing 144
- 2023-07-03 filing 144
- 2023-07-03 filing 144
- 2023-07-03 filing 144
- 2023-06-15 filing 8-K items 5.07
- 2023-06-13 filing 144
- 2023-06-13 filing 144
- 2023-06-13 filing 144
- 2023-06-13 filing 144
- 2023-06-13 filing 144
- 2023-06-13 filing 144
- 2023-06-02 filing 144
- 2023-05-04 filing Quarterly report (10-Q)
- 2023-05-04 filing 8-K items 2.02,9.01
- 2023-04-28 filing DEFA14A
- 2023-04-28 filing ARS
- 2023-04-28 filing Proxy statement
- 2023-03-02 filing Annual report (10-K)
- 2023-03-02 filing 8-K items 2.02,9.01
- 2023-01-09 filing 8-K items 7.01,9.01
- 2022-12-16 filing 8-K items 8.01
- 2022-12-13 filing SC 13D/A
- 2022-12-13 filing 8-K items 1.01,3.02,9.01
- 2022-12-09 filing 8-K items 7.01,9.01
- 2022-12-08 filing 8-K items 7.01,9.01
- 2022-11-10 filing 8-K items 8.01,9.01
- 2022-11-03 filing Quarterly report (10-Q)
- 2022-11-03 filing 8-K items 2.02,9.01
- 2022-09-22 filing 8-K items 1.01
- 2022-08-10 filing 8-K items 7.01
- 2022-08-04 filing Quarterly report (10-Q)
- 2022-08-04 filing 8-K items 2.02,9.01
- 2022-08-02 officer change 8-K items 5.02
- 2022-08-02 filing 424B3
- 2022-08-01 filing EFFECT
- 2022-07-28 filing CORRESP
- 2022-07-27 filing UPLOAD
- 2022-07-25 filing S-3
- 2022-06-17 filing 8-K items 5.07
- 2022-05-05 filing Quarterly report (10-Q)
- 2022-05-05 filing 8-K items 2.02,9.01
- 2022-04-29 filing DEFA14A
- 2022-04-29 filing Proxy statement
- 2022-03-15 filing SC 13D/A
- 2022-03-14 filing 8-K items 1.01,3.02,8.01,9.01
- 2022-03-03 filing Annual report (10-K)
- 2022-03-03 filing 8-K items 2.02,9.01
- 2022-01-10 filing 8-K items 7.01,9.01
- 2021-12-14 officer change 8-K items 5.02
- 2021-11-04 filing 8-K items 1.01,9.01
- 2021-11-04 filing 424B5
- 2021-11-04 filing Quarterly report (10-Q)
- 2021-11-04 filing 8-K items 2.02,9.01
- 2021-09-16 filing S-8
- 2021-08-05 filing Quarterly report (10-Q)
- 2021-08-05 filing 8-K items 2.02,9.01
- 2021-07-29 filing 8-K items 1.01,2.03
- 2021-07-14 officer change 8-K items 5.02
- 2021-07-13 filing EFFECT
- 2021-07-08 filing CORRESP
- 2021-07-08 filing UPLOAD
- 2021-07-02 filing S-3
- 2021-06-25 filing 8-K items 8.01
- 2021-06-17 officer change 8-K items 5.02,5.07,9.01
- 2011-10-04 name change Name changed from INNOVATIVE ACQUISITIONS CORP
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-09 (within 30 days) 10-Q filed (FORM 10-Q)
- 2026-11-05 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-14 (older) Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-08-06 (older) 10-Q filed (FORM 10-Q)
- 2026-08-06 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-22 (older) Form 5500 received for plan year ending 2025-12-31 (plan no. 501)
- 2026-06-22 (older) latest certified decision date in the file
- 2026-06-17 (older) earliest certified decision date in the file
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-21; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:PBYI The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
10 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1401667 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | PBYI / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 770683487 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001401667 | SEC EDGAR / IRS |
| CUSIP | 74587V107 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001401667 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $228,371,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-21 00:02 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | $31,111,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-21 00:02 UTC | Report an error |
| Total assets (at 2025-12-31) | $216,302,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-21 00:02 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $130,340,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-21 00:02 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $29,635,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-21 00:02 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 00:02 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 00:02 UTC | Report an error |
| State of incorporation | DE | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 00:02 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 00:02 UTC | Report an error |
| Business address | 10880 WILSHIRE BLVD., SUITE 1700, LOS ANGELES, CA | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 00:02 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 00:02 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | $41,802,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-21 00:02 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $71,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-21 00:02 UTC | Report an error |
| Long-term debt (at 2025-12-31) | $22,675,000 | 2025-12-31 | 10-K, XBRL LongTermDebt | as filed | 2026-11-21 00:02 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $6,023,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-21 00:02 UTC | Report an error |
| Plan (pension, plan no. 001) | PUMA BIOTECHNOLOGY, INC. 401(K) PLAN: 272 participants, assets $49,423,173 | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-21 00:02 UTC | Report an error |
| Plan (welfare, plan no. 501) | PUMA BIOTECHNOLOGY, INC. EMPLOYEE BENEFITS PLAN: 181 participants | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-21 00:02 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001437749-26-035912
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $55,056,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-09 | 0001437749-26-035912 | 2026-11-21 00:02 UTC | Report an error |
| Net income (loss) | $5,956,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-09 | 0001437749-26-035912 | 2026-11-21 00:02 UTC | Report an error |
| Interest expense | $0 | 3 months ended 2026-09-30 | 10-Q | 2026-11-09 | 0001437749-26-035912 | 2026-11-21 00:02 UTC | Report an error |
| Cash and cash equivalents | $41,548,000 | at 2026-09-30 | 10-Q | 2026-11-09 | 0001437749-26-035912 | 2026-11-21 00:02 UTC | Report an error |
| Debt due in the next 12 months (from an earlier report) | $11,342,000 | at 2026-03-31 | 10-Q | 2026-05-07 | 0001437749-26-015633 | 2026-11-21 00:02 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-09 Filing 10-Q filed (FORM 10-Q)
- 2026-11-05 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-14 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-08-06 Filing 10-Q filed (FORM 10-Q)
- 2026-08-06 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-22 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 501)
- 2026-06-22 Record latest certified decision date in the file
- 2026-06-17 Record earliest certified decision date in the file
- 2026-06-16 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-05-07 Filing 10-Q filed (FORM 10-Q)
- 2026-05-07 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-28 Filing DEFA14A filed (FORM DEFA14A)
- 2026-04-28 Filing ARS filed (FORM ARS)
- 2026-04-28 Filing DEF 14A filed (FORM DEF 14A)
- 2026-04-07 Filing PRE 14A filed (FORM PRE 14A)
- 2026-02-26 Filing 10-K filed (FORM 10-K)
- 2026-02-26 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-11-06 Filing 10-Q filed (FORM 10-Q)
- 2025-11-06 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-08-07 Filing 10-Q filed (FORM 10-Q)
- 2025-08-07 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-08-07 Filing 10-Q/A filed (FORM 10-Q/A)
- 2025-06-24 Filing 8-K filed: Item 5.03 charter or bylaw amendment; Item 9.01 exhibits
- 2025-06-13 Filing 8-K filed: Item 5.07 shareholder vote
- 2025-05-09 Filing 8-K filed: Item 5.02 officer or director change
6 earlier entries
- 2025-05-08 Filing 10-Q filed (FORM 10-Q)
- 2025-05-08 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-04-28 Filing DEFA14A filed (FORM DEFA14A)
- 2025-04-28 Filing ARS filed
- 2014-10-01 Record plan effective date: PUMA BIOTECHNOLOGY, INC. EMPLOYEE BENEFITS PLAN
- 2012-01-01 Record plan effective date: PUMA BIOTECHNOLOGY, INC. 401(K) PLAN
8-K item text, as filed (excerpts)
- 2026-11-05 8-K Item 2.02
Results of Operations and Financial Condition. On November 5, 2026, Puma Biotechnology, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein. The information in this Item 2.02, including the accompanying exhibit, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated by reference into any filing pursuant to the… the 8-K · retrieved 2026-11-21 00:02 UTC - 2026-08-06 8-K Item 2.02
Results of Operations and Financial Condition. On August 6, 2026, Puma Biotechnology, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein. The information in this Item 2.02, including the accompanying exhibit, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated by reference into any filing pursuant to the Securities… the 8-K · retrieved 2026-11-21 00:02 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
Breach states (2)
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchPuma Biotechnology, Inc · exact legal name · sx:brst:in:h7100b7b8e045 Compare
- possible matchPuma Biotechnology, Inc. · exact legal name · sx:brst:md:ITU-371869-1eefed Compare
California data-breach notices (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchPuma Biotechnology, Inc. · exact legal name · sx:cabreach:sb24-566823 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | ACORN CAPITAL ADVISORS, LLC | $33,504,835 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:02 UTC | Report an error |
| 2 | BlackRock, Inc. | $30,856,410 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:02 UTC | Report an error |
| 3 | AMERICAN CENTURY COMPANIES INC | $18,815,168 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:02 UTC | Report an error |
| 4 | RENAISSANCE TECHNOLOGIES LLC | $14,891,687 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:02 UTC | Report an error |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | $14,887,065 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:02 UTC | Report an error |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | $14,805,608 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:02 UTC | Report an error |
| 7 | DIMENSIONAL FUND ADVISORS LP | $12,311,629 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:02 UTC | Report an error |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | $10,864,667 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:02 UTC | Report an error |
| 9 | O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $9,113,880 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:02 UTC | Report an error |
| 10 | STATE STREET CORP | $7,722,058 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:02 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
DOL H-1B (LCA) · WARN NOT HELD12. Labor
| Measure | Value | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|
| Employer name (as filed) | Puma Biotechnology, Inc | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-21 00:02 UTC | Report an error |
| Certified LCAs | 4 | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-21 00:02 UTC | Report an error |
| Certified LCAs later withdrawn | 0 | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-21 00:02 UTC | Report an error |
| Total worker positions on certified LCAs | 4 | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-21 00:02 UTC | Report an error |
| Top job titles (title, LCA count) | Manager, Quality Assurance Validation (3); Manager, QA Validation (1) | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-21 00:02 UTC | Report an error |
| Wage offered, annualized (n, min, median, max) | median $161,804 (range $156,437-$199,867, 4 filings) | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-21 00:02 UTC | Report an error |
| Worksite states | CA | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-21 00:02 UTC | Report an error |
Unconfirmed: these labor figures (positions, worksite states, certified LCAs later withdrawn) are as read from DOL's quarterly LCA disclosure file. Seraphix's independent second check of them is not finished (11-19); they are shown as filed, not as verified.
WARN layoff notices: not held yet.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
7 state and city records carry this company's exact name, from 5 sources. Possible matches only.
California business registrations (2)
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchPUMA BIOTECHNOLOGY, INC. · exact legal name · sx:cabiz:la:0002592358-0001-6 Compare
- possible matchPuma Biotechnology, Inc. · exact legal name · sx:cabiz:sf:1165125-10-171-1077981 Compare
State licences (2)
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchPUMA BIOTECHNOLOGY, INC. · exact legal name · sx:elic:ctcred:2535455 Compare
- possible matchPUMA BIOTECHNOLOGY, INC. · exact legal name · sx:elic:ctcred:1353586 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchPuma Biotechnology, Inc. · exact legal name · sx:ctgov:h3250d9879f69a8a4 Compare
New York corporations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchPUMA BIOTECHNOLOGY, INC. · exact legal name · sx:nydos:4827237 Compare
USAspending (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchPUMA BIOTECHNOLOGY, INC. · exact legal name · sx:usaspending:JLJDGN4NRBP3 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1401667.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001401667. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.